Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Montelukast + cetirizine is a fixed-dose combination of two oral small molecule drugs used primarily for the treatment and prevention of allergic conditions such as seasonal allergic rhinitis and, in some cases, thyroid eye disease. Montelukast is a leukotriene receptor antagonist that blocks cysteinyl leukotriene receptors, reducing inflammation and bronchoconstriction. Cetirizine is a second-generation antihistamine that selectively antagonizes histamine H1 receptors, thereby reducing symptoms like sneezing, itching, rhinorrhea, and congestion. The combination has been shown to be more effective than cetirizine alone in preventing certain allergy symptoms (such as eye itching and nasal symptoms) when started prophylactically before allergen exposure[1][3]. It may also have utility in managing mild to moderate orbital congestion in thyroid eye disease[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on montelukast + cetirizine.